⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189271 | 1.00 | — | — | |
| SCHEMBL12198649 | 1.00 | — | — | |
| SCHEMBL12330407 | 0.86 | — | — | |
| SCHEMBL1247281 | 0.85 | — | — | |
| SCHEMBL1247092 | 0.79 | — | — | |
| SCHEMBL12022924 | 0.76 | — | — | |
| SCHEMBL12230998 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL29189783 | 0.71 | MEN1 (0.30) | — | |
| SCHEMBL29951544 | 0.71 | — | — | |
| SCHEMBL3372053 | 0.71 | LRRK2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | claimed |
| EP-2556056-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | claimed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | claimed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | claimed |
| US-20090047252-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-02-19 | — | — | US | claimed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2009005690-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| US-20240208909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| US-20210309619-A1 | ISOXAZOLIN-5-ONE DERIVATIVES AND HERBICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-10-07 | — | — | US | disclosed |
| US-11109593-B2 | Isoxazolin-5-one derivative and herbicide containing same as active ingredient | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-09-07 | — | — | US | disclosed |
| EP-3828176-A1 | ISOXAZOLIN-5-ONE DERIVATIVE, AND HERBICIDE CONTAINING SAME AS ACTIVE INGREDIENT | Hokko Chemical Industry Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-0415642-B1 | Glutarimides | ROHM & HAAS (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0659181-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5393735-A | N-(halo-oxy-)phenyl substituted cyclic imides | ROHM AND HAAS COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| WO-1994005639-A1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |